Inovio’s reinvention falls flat

Inovio’s decision two years ago to pivot away from some therapeutic cancer vaccines looked sensible – the problem now might be the other vaccine projects it pivoted to.

Data released yesterday on the group’s lead asset, VGX-3100, raise questions about whether this therapy is approvable, let alone commercially viable, and the group’s shares opened down 8% this morning.